Lubeck D P
Stanford University School of Medicine, Division of Immunology and Rheumatology, Palo Alto, CA 94304.
Curr Opin Rheumatol. 1991 Apr;3(2):286-90. doi: 10.1097/00002281-199104000-00013.
It is difficult to objectively and comprehensively measure the effects of the rheumatic diseases or their treatment. The concept of patient outcome measurement now encompasses many components: physical health, mental health, everyday functioning, general perceptions of well-being, treatment side effects, and cost-versus-benefit. Accordingly, a major research effort has been directed toward developing methods for the measurement of health status and patient outcome in arthritis and other rheumatologic diseases. The intent of this effort is to produce standard measures for evaluating disease impact, treatment impact, and costs of care. Numerous questionnaire-based instruments have appeared for clinical researchers to use, but they are couched in unfamiliar jargon and use terms such as "indirect costs," "lost productivity," and "quality-of-life." As these articles appear in the literature and clinical investigators include such measures in their studies or clinical trials, a review of the terms and an evaluation of these measures appears timely. This report describes the present state of the art, emerging problems, and future directions.
客观全面地衡量风湿性疾病及其治疗效果颇具难度。患者预后测量的概念如今涵盖诸多要素：身体健康、心理健康、日常功能、对幸福感的总体认知、治疗副作用以及成本效益。相应地，一项重大研究工作致力于开发用于测量关节炎和其他风湿性疾病健康状况及患者预后的方法。此项工作的目的是制定评估疾病影响、治疗影响及护理成本的标准措施。众多基于问卷的工具已出现供临床研究人员使用，但它们使用的是陌生的专业术语，如“间接成本”“生产力损失”和“生活质量”。随着这些文章在文献中出现，临床研究人员在其研究或临床试验中纳入此类测量方法，对这些术语进行综述并评估这些测量方法显得很及时。本报告描述了当前的技术水平、新出现的问题及未来方向。
